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Objective: Spinal cord injury (SCI) remains a source of morbidity after thoracoabdominal aortic reconstruction. These
studies were designed to determine whether PJ34, a novel ultrapotent inhibitor of the nuclear enzyme poly(adenosine
diphosphate ribose) polymerase (PARP) could modulate neurologic injury after thoracic aortic ischemia reperfusion
(TAR) in a murine model of SCI.
Methods: Forty-one anesthetized male mice were subject to thoracic aortic occlusion (11 minutes) through a cervical
mediastinotomy followed by 48 hours of reperfusion (TAR) under normothermic conditions. PJ34-treated mice (PJ, n
 12) were given 10 mg/kg PJ34 intraperitoneally 1 hour before ischemia and 1 hour after unclamping. The control
group (UN, n  21) received normal saline intraperitoneally 1 hour before ischemia and 1 hour after unclamping. Sham
animals (n  10) were subject to thoracic aortic exposure with no aortic clamping and similar intraperitoneal normal
saline injections. PARP-1/ (KO, n 8)mice were subjected to the same conditions as theUNmice. Blinded observers
rated murine neurologic status after TAR by using an established rodent paralysis scoring system. Murine spinal cords
were subjected to cytokine (GRO-1) protein analysis as a marker of inflammation and immunohistochemical analysis
(hematoxylin-eosin and PAR staining). Paralysis scores (PS) and GRO-1 levels were compared with analysis of variance,
and survival data were compared with 2.
Results: Immediately after TAR, UN and PJ mice had severe neurologic dysfunction (PS  5.8  0.1 and 4.6  0.6,
respectively; P > .05), which was significantly worse than the KO mice (PS  1.0  0.7, P < .001). After 6, 24, and 48
hours KO mice had no discernable neurologic injury (PS  0). Six hours after TAR, PJ mice significantly improved (PS
 1.1  0.73, P < .001) and remained improved at 24 (PS  0.7  0.6) and 48 hours (PS  0.6  0.6). UN mice did
not improve their PS, and Sham mice showed no neurologic abnormality at any time during these experiments. The
mortality at 48 hours was 0% for PJ and KO mice, 43% for UN (P  .012), and 0% for Sham. GRO-1 levels were
significantly decreased in PJ and KO versus UN mice (UN, 583  119 vs PJ, 5.8  0 vs KO, 5.3  1.4 mg/pg; P <
.0001). Immunohistochemistry showed evidence of decreased PAR staining and ventral motor neuron injury in PJ mice.
Conclusions: Genetic deletion of PARP or inhibition of its activity (PJ34) rescued neurologic function in mice subjected
to TAR. PARP inhibition might represent a novel therapeutic approach for prevention of SCI after TAR. (J Vasc Surg
2005;41:99-107.)
Clinical relevance: Because paralysis caused by spinal cord ischemia remains a serious complication of thoracic aortic
aneurysm repair, effective therapeutic strategies to prevent or decrease its incidence are desirable. Although there is hope
that the systemic complications associated with open thoracic aortic aneurysm repair will be avoided by managing these
lesions with catheter-based endovascular approaches, the initial experiences suggest that spinal cord ischemia might
continue to be an unresolved clinical problem.Spinal cord injury (SCI) remains a source of morbidity
after thoracoabdominal aortic reconstruction. These stud-
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doi:10.1016/j.jvs.2004.10.040ies were designed to determine whether PJ34, a novel
ultrapotent inhibitor of the nuclear enzyme poly(adenosine
diphosphate ribose) polymerase (PARP) could modulate
neurologic injury after thoracic aortic ischemia reperfusion
(TAR) in a murine model of SCI. PARP is constitutively
expressed in the nuclei of a variety of tissues and organs
including the central nervous system. The activity of the
enzyme is stimulated by DNA single strand breaks, as seen
during ischemic and reperfusion injury1 (Fig 1). PARP
transfers adenosine diphosphate (ADP) ribose from nico-
tinamide dinucleotide (NAD) to nuclear proteins, result-
ing in formation of nicotinamide, which inhibits PARP
activity and can be recycled to NAD in an energy consum-
ing metabolic cycle, which rapidly depletes intracellular
adenosine triphosphate (ATP).2 PARP activity has also
been shown to be involved in the regulation of inflamma-
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tant transcription factors, notably nuclear factor kappa B.3
A common result of PARP activation is cellular dysfunction
leading to necrosis; however, the activation of the PARP
enzyme has also been implicated in the development of
apoptosis.4 PARP activation has been documented in ani-
mal models of ischemic myocardium,5 intestines,6and renal
and central nervous system ischemia-reperfusion injury.7
Independent studies have demonstrated the role of PARP
in endotoxin and zymogen mediated acute respiratory dis-
tress syndrome in rodents.8
Animal studies have shown that inhibition of the PARP
enzyme can limit cerebral infarct size in a stroke model.9
Most PARP inhibitors act as competitive inhibitors of the
enzyme, ie, the inhibitors block NAD binding to the
catalytic domain of the enzyme, although some benz-
amides have been shown to exert additional effects such as
inhibition of the binding of PARP to DNA.10 Even though
there are many different PARP isoforms, the issue of selec-
tivity has not been a problem because the active catalytic
center of PARP is highly conserved. PARP inhibitors fall
into the categories of monoaryl amides and bicyclic, tricy-
clic, or tetracyclic lactams. An inherent disadvantage of
these planar heteroaromatic compounds is their poor solu-
bility in water and organic solvents. Recentmodifications of
the tricyclic 1,8-napthalimide derivatives and (5H)-
phenanthridin-6-ones have resulted in the development of
PJ34, a potent, water soluble, orally bioavailable with
marked in vivo activity. PJ34 and related compounds in-
hibit PARP activation in whole blood cell based assays in
Fig 1. Pathways to PARP activation. PARP is activated by DNA
single strand breaks, which develop in response to intracellular/
extracellular generation of reactive oxygen and/or nitrogen spe-
cies. PARP activation exacerbates underlying energy crisis brought
on by pre-existing ischemia or mitochondrial dysfunction during
tissue reperfusion. Depletion of reduced nicotinamide adenine
dinucleotide and ATP contributes to tissue injury, cell necrosis,
and endothelial dysfunction.the concentration range of 10 nmol/L to 1 mol/L, witha median effective concentration in the 100 to 300 nmol/L
range. They exert their in vivo anti-inflammatory and anti-
reperfusion actions in a dose range of 3 to 30 mg/kg.11,12
The solubility of PJ34 in saline, its intraperitoneal absorp-
tion, and its ability to effectively inhibit PARP in biologic
systems at dosages in the lowmilligram per kilogram dosing
range made this compound an attractive agent for study in
this model.3,12 Many investigations have shown that the
tissue protective effect of the novel, ultrapotent PARP
inhibitor PJ34 correlates with its ability to decrease PARP
activity in vivo.13
Despite considerable advances during the past decade,
SCI complicating extensive thoracic aortic aneurysm sur-
gery remains an unsolved problem. The multitude of ad-
juncts and operative strategies reviewed elsewhere14 di-
rected against SCI is testimony to the fact that there
remains no consensus on the optimal strategy to prevent
this complication. The widespread distribution of the
PARP enzyme, combined with its proven protective effects
on a multitude of organs, makes PARP inhibition an attrac-
tive candidate for potential prevention of SCI in thoraco-
abdominal surgery. This study was designed to test the
hypothesis that PARP inhibition would limit the incidence
of SCI in a mouse model of thoracic aortic ischemia reper-
fusion.
METHODS
Experimental preparation. To achieve thoracic aortic
ischemia and reperfusion (TAR), male 129S-Adprt1tm1Zqw
mice (PARP-1/15) and their control strain 129S1/SvImJ
(both strains from Jackson Laboratory, Bar Harbor, Maine),
age 8 weeks and weighing 28 to 30 g, were used for these
experiments. Animal care and experimental procedures com-
plied with “Principles of Laboratory Animal Care” (Guide for
theCare andUse of LaboratoryAnimals,National Institutes of
Health publication 86-23, 1985) and were approved by the
Massachusetts General Hospital animal studies committee.
Anesthesia was administered with an intraperitoneal injection
of sodium pentobarbital (75 mg/kg). Five units of heparin
(170 IU/kg) was injected subcutaneously 5 minutes before
the procedure. Temperature was maintained at 37.5°C 
0.5°C, and animalswere allowed tobreathe roomair through-
out the experiment. TAR was achieved through a cervical
mediastinotomy slightly modified from a technique initially
described by Lang-Lazdunski et al.16 Modifications of the
protocol used by Lang-Lazdunski et al include use of intra-
peritoneal pentobarbital anesthesia rather than inhaled halo-
thane to facilitate positioning for noninvasive laser Doppler
imaging. Qualitative confirmation of lower extremity hypo-
perfusion after aortic clamping and reperfusion after removal
of the clamp was obtained by using laser Doppler imaging.
The thoracic aorta was occluded for 11 minutes as described
by Lang-Lazdunski. Control strain mice were assigned to
study groups as follows: treated animals (PJ, n  12) were
administered the PARP inhibitor N-(6-oxo-5,6-dihydropen-
anthridin-2-yl)-2-(N,N-dimethylamino)acetamide (PJ34;
Calbiochem, Spring Valley, Calif) 10 mg/kg (0.3 mg in 0.3
mL normal saline) intraperitoneally 1 hour before the proce-
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n  21) and sham mice (Sham, n  10) received vehicle
(normal saline, 0.3 mL) under identical conditions; in the
Sham-operated group, there was no aortic and subclavian
artery occlusion. PARP / mice (KO, n  8) received
vehicle (normal saline, 0.3 mL) as described earlier. All exper-
imental groups had the same volume of fluid during the
perioperative period. Animals were killed at 48 hours of reper-
fusion with an intraperitoneal injection of sodium pentobar-
bital (100 mg/kg).
Laser Doppler imaging. To monitor lower body per-
fusion and to confirm TAR, laser Doppler imaging was
performed. The laser Doppler scanner was mounted on a
movable rack exactly 10 cm above the lower extremities and
tails of the mice while the mice were restrained on a heated
(37°C) operating blanket. The laser beam (780 nm), re-
flected from moving red blood cells in nutritional capillar-
ies, arterioles, and venules, is detected and processed to
provide a computerized, color-coded image. Mouse hind
limbs and tails were scanned with a laser Doppler Imager
(Moor Instruments Inc, Wilmington, Del; model LDI)
immediately before, during, and after applying the aortic
clamp to qualitatively document baseline perfusion and
confirm ischemia followed by reperfusion. All animals that
were found to have adequate hind limb and tail ischemia
after aortic clamping were subjected to a complete neuro-
logic assessment and survival analysis after reperfusion.
Mice that had evidence of ongoing perfusion after aortic
clamping were immediately killed and not subjected to
further experimental analysis.
Paralysis scoring scale. Mouse hind limb neurologic
function was assessed by blinded observers on awakening,
at 6 hours, 24 hours, and 48 hours. Motor functions were
graded by using a mouse paralysis score (PS) system16: (1)
walking with hind limbs: 0, normal; 1, toes flat under body
when walking but ataxia is present; 2, knuckle-walking; 3,
movements in hind limbs but unable to walk; and 4, no
movement, drags hind limbs; and (2) placing/stepping
reflex: 0, normal; 1, weak; and 2, no stepping. Each grade
was obtained by adding the scores for (1) and (2) to provide
the PS.
Histopathology. Animals were killed at 48 hours of
reperfusion as described above. The entire spinewas harvested
en bloc and fixed in 10% buffered formalin for 24 hours. The
cords were transferred to 70% alcohol. Specimens were decal-
cified for 1 week. After paraffin embedding, thin sections of
cordwere prepared from the thoracolumbar cord (T8-L5) for
immunohistochemical detection of poly(ADP ribose) forma-
tion, an immunohistochemical indicator of the activation of
PARP and examination under hematoxylin-eosin (fast blue
hematoxylin-eosin; Biomedia, Foster City, Calif). Immuno-
histochemical detection of poly(ADP ribose) was performed
in paraffin sections (3 m) after deparaffinization in xylene
and rehydrated in decreasing concentrations (100%, 95%, and
75%) of ethanol followed by a 10-minute incubation in phos-
phate-buffered saline (PBS) (pH, 7.4). Sections were treated
with 0.3% hydrogen peroxide for 15minutes to block endog-
enous peroxidase activity and then rinsed briefly in PBS.Nonspecific bindingwas blockedby incubating the slides for 1
hour in 0.25% Triton/PBS containing 2% horse serum. Poly-
(ADP ribose) was detected by using a chicken monoclonal
anti-poly(ADP ribose) antibody (Tulip Biolabs, West Point,
Pa) and isotype-matched control antibody, applied in a dilu-
tion of 1:250 for 1 hour at room temperature. After extensive
washing (3  10 min) with 0.25% Triton/PBS, immunore-
activity was detected with a biotinylated horse anti-chicken
secondary antibody and the avidin-biotin-peroxidase com-
plex, both supplied in the Vector Elite kit (Vector Laborato-
ries, Burlingame, Calif). Color was developed by using Ni-
DAB substrate-kit (Vector Laboratories). Sections were then
counterstained with nuclear fast red, dehydrated, and
mounted in Permount.17 Photomicrographs were taken with
a Zeiss Axiolab microscope (Zeiss Microscopy, Welwyn Gar-
den City, United Kingdom) equipped with a Fuji HC-300C
digital camera (Fuji Film Medical Systems, Stamford, Conn).
All immunohistochemical samples were coded and examined
and graded by an investigator in a blinded fashion.
Cord protein analysis. Protein samples were extracted
from the ischemic zone (T8-L5) of representative spinal
cords for subsequent cytokine analysis. Excised tissue was
immediately frozen, crushed into powder in liquid N2, and
then homogenized on ice (protease cocktail) and centri-
fuged at 11,000g for 30 minutes at 4°C.18 Supernatants
from these extracts were analyzed for GRO-1 by using
enzyme-linked immunosorbent assay (R & D Systems,
Minneapolis, Minn). The results were normalized to total
protein in each extract.
Statistical analysis. Survival data were calculated by
using Fisher exact t analysis at 6, 24, and 48 hours. Neuro-
logic score and GRO-1 levels between treatment groups at
each experimental interval were calculated by using analysis
of variance (ANOVA) (Kruskal-Wallis test, nonparametric
ANOVA). Post hoc analysis included the Dunn multiple
comparison test.
RESULTS
Survival. Mortality (overall 43%) was observed only in
the control, untreated mice subjected to TAR. Two UN
mice died while the clamp was on. Four UNmice died after
awakening but before the 6-hour evaluation interval. At the
6- and 24-hour intervals, there was no significant difference
between the survival of the UN and PJ mice (6 hours, P 
.522; 24 hours, P  .585); two of the three mice dying
between 24 and 48 hours were noted to have hematuria
and mesenteric infarction at necropsy. No Sham or PJ
animal (n  12) died before or after the clamps were
removed. All PARP / mice (n  8) survived the TAR
throughout the entire 48-hour period. At necropsy, no PJ
or PARP / mouse had gross evidence of hematuria or
ischemia/necrosis disease in the visceral organs. When
compared to untreated animals, PJ (P .0050, 2) and KO
mice (P  .0265, 2) had significantly better survival at 48
hours.
Paralysis scoring. The results of the neurologic injury
scoring are represented in Fig 2. All surviving UN and PJ
mice awoke with significant neurologic dysfunction (PS 
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awakening after TAR, only the KO mice had significantly
less neurologic injury than UN mice (PS 1.0 0.7, P	
.001). After 6, 24, and 48 hours KO mice had no discern-
able neurologic injury (PS  0). Six hours after TAR, PJ
mice significantly improved (PS  1.1  0.73, P 	 .001)
and remained improved at 24 (PS 0.7 0.6) and 48 (PS
 0.6  0.6) hours. UN mice did not improve their PS at
6, 24, or 48 hours, and Sham mice showed no neurologic
abnormality at any time during these experiments.
Laser Doppler imaging. Forty-one of 49 mice were
found to have completely decreased lower torso perfusion
and were subjected to reperfusion and neurologic scoring.
Eight mice (3 KO, 2 PJ, and 3 UN) were found to have
ongoing lower torso perfusion despite aortic clamping and
thus were not subjected to reperfusion, neurologic assess-
ment, or cytokine analysis.
Spinal cord histology.
Untreated control mice subjected to TAR showed ex-
tensive evidence of anterior motor neuron injury as dem-
onstrated in this representative section of the lower thora-
columbar cord (T8-L5, Fig 3). The anterior horn tissue is
pale because of destruction of the motor neurons. In con-
trast, the posterior columns and the dorsal nuclei have a
homogenous deep purple color as a result of preservation of
these structures. The histologic finding of preserved poste-
rior or sensory columns and sensory nuclei is characteristic
of the human ischemic cord syndrome. A high power
photomicrograph of an untreated mouse subjected to TAR
reveals evidence of chromalytic Nissl bodies (Fig 4, A) and
axonal spherocytosis (Fig 4, C). In contrast, Sham animals
(Fig 4, B) showed preserved motor nuclei with no evidence
Fig 2. Paralysis scoring after thoracic aortic ischemia-reperfusion.
PS was markedly decreased in the PARP / (KO) vs untreated
(UN) animals (*P 	 .001), but not PJ mice on awakening. After
awakening, the PS in the PJ mice was markedly less than in UN
mice (**P 	 .001). The KO mice were normal after 6 hours of
reperfusion.of neuronal injury.The different morphologic appearances of the thoraco-
lumbar cord in UN, KO, and PJ mice are demonstrated in
Fig 5. In the outlined section of the anterior horns in the
UNmice, there is evidence of vacuolization and a paucity of
motor nuclear cells. There is preservation of the anterior
motor neuron complex in the PJ and KO mice. Immuno-
histochemical staining for poly(ADP ribose), the catalytic
product of the PARP enzyme, revealed that there was
marked activation of the enzyme in the few identifiable
anterior motor nuclear cells visible after thoracic aortic
ischemia-reperfusion (Fig 6,C). Compared to the low basal
PARP activity detected in the Sham controls (Fig 6, A),
there were very few intact anterior motor nuclei in the cords
of UN mice (Fig 6, C). The ability of PJ34 to inhibit the
catalytic activity of the PARP enzyme in vivo was shown by
minimal poly(ADP ribose) immunostaining seen in the
inhibitor treated animals (Fig 6, B), along with intact
anterior motor nuclei.
Spinal cord cytokine levels. UN mice were found to
have markedly elevated GRO-1 levels (583  119, P 	
.0001) versus Sham (6.1  0.2 mg/pg cord protein, n 
8), KO (5.8 1.0 mg/pg, n 6), and PJ mice (5.3 1.4
mg/pg, n 6). Sham, PJ, and KOmice had extremely low
levels of GRO-1, which were not statistically different from
one another.
DISCUSSION
These experiments indicate that the PARP inhibitor
PJ34 preserves neurologic function and survival in a murine
model of TAR. The benefit of PARP inhibition was verified
by using an approach of genetic deletion of this important
nuclear enzyme. The use of transgenic mice lacking the
functional PARP enzyme has provided unequivocal data to
support its role in myocardial ischemia-reperfusion injury19
and as such provides rationale for a transgenic approach to
studying neurologic dysfunction after TAR. This report is
among the first to apply specific genetic deletion to examine
therapeutic strategies for prevention of spinal cord isch-
emia-reperfusion.20 The salvage of neurologic function by
PARP inhibition with PJ34 and PARP genetic deletion was
statistically evident after awakening and remained evident
throughout reperfusion (Fig 2). The reason for pursuing
PARP inhibition to limit spinal cord ischemia was based on
successful interventions seen in animal models of stroke,7,9
endotoxic shock,12 andmyocardial ischemia.5 Unlike other
inhibitors of PARP, PJ34 is water soluble and can be
diluted in saline (which has no antioxidant capacity). Other
potent inhibitors of PARP must be solubilized in dimethyl
sulfoxide, which can scavenge reactive oxygen metabolites
and possibly complicate experimental analysis.21 The dos-
age of PJ34 used in these experiments paralleled pre-injury
and postinjury regimen used for intravenous administration
of PJ34 in rodent model of stroke,7 endotoxemia/gut
ischemia,12 and sepsis.2 Combined pretreatment and post-
treatment regimen was favored for these experiments be-
cause of the severe systemic stress associated with TAR, the
short half-life of PJ34 in plasma7(30-minute half-life), and
because the intraperitoneal route of administration might
lumb
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Although murine neurologic function was significantly im-
proved immediately after TAR in KO and PJ mice, a
survival advantage with respect to PJ34 treatment was not
clearly evident until 48 hours. In treated animals and KO
mice, there were no deaths. In contrast, there were six early
deaths, ie, expiration with the clamp on or within 6 hours of
thoracic aortic occlusion in UN animals. A possible expla-
nation for the trend toward decreased early mortality in KO
mice andmice treated with PARP inhibitors might be based
on the physiology of thoracic aortic occlusion. Activation of
PARP during thoracic aortic occlusion might contribute to
myocardial ischemia prompted by increased myocardial
oxygen demand caused by increased afterload. We did not
specifically evaluate myocardial PARP activation in these
experiments. However, Faro et al5 have documented PARP
activation in porcine myocardium after brief periods of
ischemia-reperfusion and have shown that treatment with
PJ34 effectively ameliorates the physiologic consequences
of its activation.5 In addition to the effects of proximal
aortic occlusion on myocardial oxygen demand, the choice
of pentobarbital for anesthesia and room air for ventilation
might have also influenced early mortality surrounding
mice subjected to TAR in the absence of PJ34 treatment.
The early mortality rate reported by Lang-Lazdunski et al16
was 21%, whereas the mortality observed in these experi-
ments was 43%. We chose pentobarbital and room air over
Fig 3. Cross-sectional spinal cord anatomy of an untre
after TAR, global depletion of anterior motor neuron ce
is demonstrated in this photomicrograph of the thoracohalothane and 100% oxygen to facilitate laser Dopplerimaging. Both pentobarbital and halothane have been re-
ported to have protective effects toward spinal cord isch-
emia.22 Laser Doppler imaging was used to document
lower torso ischemia in each mouse subjected to TAR. We
identified eight mice that were ostensibly occluded by
clamps at the thoracic arch but had visual evidence of
ongoing lower torso perfusion on laser Doppler imaging.
The ongoing distal perfusion observed in the setting of
thoracic aortic cross-clamping might have been related to
microvascular clamp fatigue, clamp position, or large col-
lateral pathways through the anterior abdominal wall. To
assure consistency in the degree of ischemia for each mouse
included in these experiments, no attempts were made to
readjust the clamps to re-establish torso ischemia in these
mice. Thus the elimination of these mice from the study
and subsequent neurologic analysis provided objective con-
firmation that thoracic aortic ischemia was indeed a com-
mon factor in all mice subjected to reperfusion. This is in
contrast to the work of Lang-Lazdunski et al, who docu-
mented decreased cord perfusion by using invasive moni-
toring only in a subset of mice not subjected to further
neurologic or survival analysis.
Three of the UN mice died after 24 hours of recovery.
Necropsy showed that mesenteric ischemia might have
contributed to two of these late deaths. Prolonged mesen-
teric ischemia has been correlated with increased inflamma-
tory response after thoracic aortic aneurysm repair and has
ouse (original magnification, 10). Forty-eight hours
) with preservation of the sensory posterior columns (P)
ar spine. The dorsal sensory nuclei were preserved (D).ated m
lls (Aprovided the impetus for mesenteric shunting during com-
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and autopsy findings of mesenteric infarction strongly sug-
gest that the murine model might be more robust and
relevant for study of the complex systemic complications of
TAR in addition to spinal cord ischemia.
Although the findings in the current report parallel the
Fig 4. High power photomicrographs of the thoracolumbar
spinal cord (original magnification, 40). A, Evidence of chro-
malytic Nissl bodies in an anterior motor neuron of an untreated
mouse 48 hr after TAR (black solid arrows). B, Evidence of
preserved motor nuclei in a Sham animal (white solid arrows). C,
Axonal spherocytosis in an untreated animal 48 hr after TAR
(dotted black arrows).effect of other pharmacologic agents in a variety of animalmodels, themurinemodel usedmight havemore relevance to
the human condition. It is obvious that the murine model is
useful because it is suited for molecular manipulations with
specific knockout (ie, genetic deletions) and transgenic mice.
This model might be more relevant to the human condition
because the blood supply to themurine spinal cord is nonseg-
mental. Humans experience a unique type of spinal cord
dysfunction, ie, anterior cord syndrome after ischemia-reper-
fusion injury. In human cord ischemia-reperfusion injury, the
anterior motor neurons are damaged, and the posterior col-
umns are spared. The vertical orientation of the blood supply
Fig 5. Distal thoracic spinal cord photomicrographs (original
magnification, 10). Untreated mice show widespread depletion
of anterior motor neuron cells, whereas PJ and PARP / (KO)
mice exhibit preserved anterior motor neurons.to the human spinal cord (single anterior and dual posterior
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ing the posterior sensory columns at the expense of the ante-
rior motor neurons. In contrast, the blood supply to pigs and
rabbits is segmental and horizontal. In the pig and rabbit
model of ischemia-reperfusion, there is simultaneous motor
and sensory defect at the level of aortic clamping. In the
experiments reported in this article, histologic examination of
the spinal cords of untreated animals revealed evidence that
the posterior (or dorsal sensory) elements of the cords were
preserved after thoracic aortic occlusion (Fig 3), consistent
with the clinical finding in human patients afflicted with spinal
cord ischemia after thoracic aortic ischemia-reperfusion. PJ
mice showed no evidence of ventral motor neuronal injury
(Figs 4 and 5). PJ mice also showed minimal evidence of
PARS cleavage as compared to UN mice (Fig 6). Thus both
the anatomic and physiologic findings obtained from experi-
ments with this murine model recapitulate anterior cord syn-
drome in humans16 and are likely to be extremely relevant to
the clinical conditions associated with thoracic aortic isch-
emia-reperfusion. Furthermore, because sensory neurogenic
stimuli have been implicated in local and systemic response to
inflammation,24 animalmodels of spinal corddysfunction that
preserve the sensory columns might be important to accu-
rately study the systemic and local consequences of spinal cord
ischemia-reperfusion. One potential drawback to the murine
model of TAR is the inability to continuously monitor hemo-
dynamic variables associated with the physiologic stress of
TAR in conjunction with neurologic assessment. Many of the
salutary effects seen in this model might be due primarily to
the ability of PJ34 to modulate hemodynamic parameters
relevant to the stress of TAR, such as cardiac output, rather
than a direct effect on the spinal cord tissue. However, if
extensive intravascular thrombosis or hemodynamic failure
contributed to mortality in the UN mice, necropsy should
have revealedmore extensive gross organ injury, particularly in
the 48-hour survivors, where the duration of reperfusion
would have allowed for the no-reflow phenomenon to
progress to tissue necrosis.
Injury to the spinal cord is complicated by inflamma-
tory mechanisms mediated by influx of monocytes and
macrophages after the secretion of cytokines and chemo-
kines.25,26 Detailed immunohistochemical analysis sug-
gests that microglia cells, not peripheral inflammatory cells,
are the main source for cytokine and chemokines in the
central nervous system.27 Acute central nervous system
injury has been associated with transient release of inflam-
matory mediators such as interleukin-1 and tumor necrosis
factor
 during the first few hours of ischemia.28 In con-
trast to the cytokine profile during acute central nervous
system injury, GRO-1, also known as KC, the murine
equivalent of human interleukin-8, is a CXC chemokine
implicated in chronic inflammatory processes within the
central nervous system.29 GRO-1 was markedly increased
in the spinal cord tissue of UNmice, as compared to Sham,
KO, and PJ mice. This finding indicates that PARP inhibi-
tion or genetic deletion successfully decreases the cytokine
response in the spinal cord after TAR. Although knockout
mice have been used to delineate a role for Tissue Plasmin-ogen Activator and the pro-apoptotic protein Bax in medi-
ating spinal cord responses to hemitransection,30,31 this
report is among the first to use genetic deletion20 for the
primary purpose of studying spinal cord responses to isch-
Fig 6. PAR immunohistochemistry murine spinal cord at 48 hr
(original magnification, 40). A, Sham mouse cord demonstrat-
ing many anterior motor neurons and no intense PAR staining. B,
PJ mouse with abundant anterior motor nuclei and sparse PAR
staining. C, Untreated mouse cord demonstrating few anterior
motor nuclei and focal intense PARS staining.emia followed by reperfusion.
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etiology of neurologic dysfunction after TAR, firmly
implicating a role for the DNA repair enzyme PARP in
the etiology of SCI. On the basis of what is known about
PARP consumption of ATP and NAD during energy
crises, we suspect that PJ34 decreases intracellular en-
ergy depletion in spinal cord tissues during TAR, which
might decrease cellular stress during ischemia-reperfu-
sion, resulting in decreased inflammatory response. The
double-edged sword of PARP activity suggests that its
inhibition in a number of clinical conditions such as
arthritis, sepsis, diabetes, stroke, inflammatory bowel
disease, and spinal cord ischemia might provide a useful
venue for intervention in human diseases. Before potent
PARP inhibitors can be used in humans, crucial safety
issues must be addressed. PARP has been implicated in
DNA repair and maintenance of genomic integrity;
therefore one possible risk associated with long-term
PARP inhibition might be increased mutation rate, pos-
sibly associated with cancer formation. PARP-deficient
mice have not been reported to have an increased occur-
rence of spontaneous tumors; however, increased inci-
dences of chemically induced tumors have been identi-
fied in these mice.3 Issues such as cancer risk are largely
mitigated by short-term treatment with PARP inhibitors
in acute life-threatening indications such as stroke, myo-
cardial ischemia, and repair of thoracic aortic aneurysms.
Because paralysis caused by spinal cord ischemia
remains a serious complication of thoracic aortic aneu-
rysm repair, effective therapeutic strategies to prevent or
decrease its incidence are desirable. Although there is
hope that the systemic complications associated with
open thoracic aortic aneurysm repair will be avoided by
managing these lesions with catheter-based endovascular
approaches, the initial experiences suggest that spinal
cord ischemia might continue to be an unresolved clin-
ical problem.32
REFERENCES
1. Szabo C. Potential role of the peroxynitrate-poly(ADP-ribose) syn-
thetase pathway in a rat model of severe hemorrhagic shock. Shock
1998;9:341-4.
2. Goldfarb RD,Marton A, Szabo E, Virag L, Salzman AL, Glock D, et al.
Protective effect of a novel, potent inhibitor of poly(adenosine 5’-
diphosphate-ribose) synthetase in a porcine model of severe bacterial
sepsis. Crit Care Med 2002;30:974-80.
3. Virag L, Szabo C. The therapeutic potential of poly(ADP-Ribose)
polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
4. Chiarugi A, Moskowitz MA. Cell biology: PARP-1—a perpetrator of
apoptotic cell death? Science 2002;297:200-1.
5. Faro R, Toyoda Y, McCully JD, Jagtap P, Szabo E, Virag L, et al.
Myocardial protection by PJ34, a novel potent poly (ADP-ribose)
synthetase inhibitor. Ann Thorac Surg 2002;73:575-81.
6. Liaudet L, Szabo A, Soriano FG, Zingarelli B, Szabo C, Salzman AL.
Poly (ADP-ribose) synthetase mediates intestinal mucosal barrier dys-
function after mesenteric ischemia. Shock 2000;14:134-41.
7. Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dirnagl U, Szabo C,
et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-
ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int
J Mol Med 2001; 7:255-60.
8. Liaudet L, Pacher P, Mabley JG, Virag L, Soriano FG, Hasko G, et al.
Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism oflipopolysaccharide-induced acute lung inflammation. Am J Respir Crit
Care Med 2002;165:372-7.
9. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J,
et al. Poly(ADP-ribose) polymerase gene disruption renders mice
resistant to cerebral ischemia. Nat Med 1997;3:1089-95.
10. McLick J, Hakam A, Bauer P, Zacharias D, Glusker J. Benzamide -DNA
interactions: deductions from binding, enzyme kinetics and from Xray
structural analysis of a 9-ethyladenine adduct. Biochem Biophys Acta
1987;909:71-83.
11. Mabley JG, Jagtap P, Perretti M, Getting SJ, Salzman AL, Virag L, et al.
Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-
ribose) polymerase. Inflamm Res 2001;50:561-9.
12. Jagtap P, Soriano FG, Virag L, Liaudet L, Mabley J, Szabo E, et al.
Novel phenanthridinone inhibitors of poly (adenosine 5’-diphosphate-
ribose) synthetase: potent cytoprotective and antishock agents. Crit
Care Med 2002;30:1071-82.
13. Szabo G, Bahrle S, Stumpf N, Sonnenberg K, Szabo EE, Pacher P, et al.
Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury
after heart transplantation. Circ Res 2002;90:100-6.
14. Cambria RP, Davison JK. Regional hypothermia for prevention of
spinal cord ischemic complications after thoracoabdominal aortic sur-
gery: experience with epidural cooling. Semin Thorac Cardiovasc Surg
1998;10:61-5.
15. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D,
Schweiger M, et al. Mice lacking ADPRT and poly(ADP-ribosyl)a-
tion develop normally but are susceptible to skin disease. Genes Dev
1995;9:509-20.
16. Lang-Lazdunski L, Matsushita K, Hirt L, Waeber C, Vonsattel JP,
Moskowitz MA, et al. Spinal cord ischemia: development of a model in
the mouse. Stroke 2000;31:208-13.
17. Xiao C, Chen M, Zsengeller Z, Szabo C. Poly(ADP-Ribose) polymer-
ase contributes to the development of myocardial infarction in diabetic
rats and regulates the nuclear translocation of apoptosis-inducing fac-
tor. J Pharm Exp Ther 2004;310:498-504.
18. Bernik T, Friedman S, Ochani M, DiRaimo R, Susarla S, Czura C, et al.
Cholinergic antiinflammatory pathway inhibition of tumor necrosis
factor during ischemia reperfusion. J Vasc Surg 2002;36:1231-6.
19. Zingarelli B, Salzman AL, Szabo C. Genetic dysruption of Poly (ADP)
ribose synthetase inhibits the expression of P-selectin and intercellular
adhesion molecule in myocardial ischemia/reperfusion injury. Circ Res
1998;83:85-94.
20. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F,
Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis
in mice and humans and protects motoneurons against ischemic death.
Nat Genet 2003;34:383-94.
21. Banasik M, Ueda K. Dual inhibitory effect of dimethylsulfoxide on poly
(ADP-ribose) synthase. J Enzyme Inhib 1999;14:239-50.
22. de Haan P, Kalkman CJ, Jacobs MJ. Pharmacologic neuroprotection in
experimental spinal cord ischemia: a systematic review. J Neurosurg
Anesthesiol 2001;13:3-12.
23. Welborn MB, Oldenburg HS, Hess PJ, Huber TS, Martin TD,
Rauwerda JA, et al. The relationship between visceral ischemia,
proinflammatory cytokines, and organ injury in patients undergoing
thoracoabdominal aortic aneurysm repair. Crit Care Med 2000;28:
3191-7.
24. Tracey K. The inflammatory reflex. Nature 2002;420:853-8.
25. Klusman I, Schwab ME. Effects of pro-inflammatory cytokines in
experimental spinal cord injury. Brain Res 1997;762:173-84.
26. Pan JZ, Ni L, Sodhi A, Aguanno A, Young W, Hart RP. Cytokine
activity contributes to induction of inflammatory cytokine mRNAs in
spinal cord following contusion. J Neurosci Res 2002;68:315-22.
27. Bartholdi D, Schwab ME. Expression of pro-inflammatory cytokine
and chemokine mRNA upon experimental spinal cord injury in
mouse: an in situ hybridization study. Eur J Neurosci 1997;9:1422-
38.
28. Clark W, Lutsep H. Potential of anticytokine therapies in central
nervous system ischemia. Expert Opin Biol Ther 2001;1:227-37.
29. Andrews DM, Matthews VB, Sammels LM, Carrello AC, McMinn PC.
The severity of murray valley encephalitis in mice is linked to neutrophil
JOURNAL OF VASCULAR SURGERY
Volume 41, Number 1 Casey et al 107infiltration and inducible nitric oxide synthase activity in the central
nervous system. J Virol 1999;73:8781-90.
30. Abe Y, Nakamura H, Yoshino O, Oya T, Kimura T. Decreased neural
damage after spinal cord injury in tPA deficient mice. J Neurotrauma
2003;20:43-57.
31. Dong H, Fazzaro A, Xiang C, Korsmeyer S, Jacquin MF, McDonald J.
Enhanced oligodendrocyte survival after spinal cord injury in Bax-deficient mice andmice with delayed wallerian degeneration. J Neurosci
2003;23:8682-91.
32. Carroccio A, Ellozy S, Spielvogel D, Marin ML, Hollier L. Endovascu-
lar stent grafting of thoracic aortic aneurysms. Ann Vasc Surg 2003;17:
473-8.Submitted Mar 14, 2004; accepted Oct 13, 2004.
